Frederic Cren, Inventiva CEO

In­ven­ti­va signs over Chi­na NASH rights to Sino Bio­pharm in pos­si­ble $300M+ deal

More than two years af­ter claim­ing a Phase II win in one of the most chal­leng­ing dis­eases faced in biotech, In­ven­ti­va is hand­ing over rights in sev­er­al Asian mar­kets to a more on-site com­pa­ny.

In­ven­ti­va and Sino Bio­pharm joint­ly an­nounced the deal Wednes­day af­ter mar­ket close, where In­ven­ti­va will hand over de­vel­op­ment and com­mer­cial­iza­tion rights for NASH can­di­date lan­i­fi­bra­nor to Sino Bio­pharm sub­sidiary Chia Tai-Tian­qing Phar­ma­ceu­ti­cal Group (CT­TQ). Rights in­clude those in Chi­na, Hong Kong, Macau and Tai­wan.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.